News for Aclaris Therapeutics, Inc. (ACRS)

- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer -

On June 30, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction by acquiring an additional 4,110,674 shares of Aclaris Therapeutics Inc

On July 10, 2025, Piper Sandler analyst Biren Amin initiated coverage on Aclaris Therapeutics (ACRS) with an "Overweight" rating. This action marks a new covera

Piper Sandler analyst Biren Amin has taken up coverage of Aclaris Therapeutics (ACRS) with an Overweight rating, setting a price target of $6. Currently, ACRS s

WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025.

WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today

Aclaris Therapeutics (ACRS) has launched a new clinical program for its investigational drug, ATI-052, which aims to be a leading candidate in the category of b

Aclaris Therapeutics, under the ticker ACRS, has commenced a Phase 2 clinical trial to evaluate the efficacy and safety of bosakitug in treating patients with m

- Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal

Market Analysis by covering: Summit Therapeutics PLC, TherapeuticsMD Inc, Viking Therapeutics Inc, Aclaris Therapeutics Inc. Read 's Market Analysis on Investing.com

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Following the recent release of its first-quarter results, Aclaris Therapeutics (ACRS) has experienced a revision in its stock price target. Analyst Raghuram Se

Scotiabank's analyst, Louise Chen, has revised the price target for Aclaris Therapeutics (ACRS) from $15 to $9 while maintaining an Outperform rating. This adju

**media[620227]**

Aclaris Therapeutics (ACRS) reports Q1 GAAP EPS of -$0.12 and revenue of $1.46M (-39.2% Y/Y). Cash reserves expected to fund operations through H1 2028.

Aclaris Therapeutics (ACRS) has named Jesse Hall, M.D. as its new Chief Medical Officer. Dr. Hall brings a wealth of expertise in medical and clinical developme

**media[601437]**

WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. ( ACRS), a clinical-stage biopharmaceutical company focused on developing novel prod

Aclaris (ACRS) delivered earnings and revenue surprises of 68.75% and 313.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?